Edward J. Dulac III - 20 Dec 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Financial Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
20 Dec 2021
Net transactions value
-$445,818
Form type
4
Filing time
21 Dec 2021, 15:08:47 UTC
Previous filing
22 Nov 2021
Next filing
13 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $512,802 +14,437 +13% $35.52* 126,381 20 Dec 2021 Direct F1
transaction FATE Common Stock Sale $958,620 -15,977 -13% $60.00* 110,404 20 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -14,437 -10% $0.000000 128,238 20 Dec 2021 Common Stock 14,437 $35.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.
F2 The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.